{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:52:25Z","timestamp":1761519145216,"version":"build-2065373602"},"reference-count":77,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2016,1,21]],"date-time":"2016-01-21T00:00:00Z","timestamp":1453334400000},"content-version":"vor","delay-in-days":20,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2016,1]]},"abstract":"<jats:p>Antibody\u2010drug conjugates (<jats:styled-content style=\"fixed-case\">ADC<\/jats:styled-content>s) combine highly specific monoclonal antibodies with potent cytotoxic drugs. Their synergy allows for targeted delivery of toxic drugs to cancer cells while sparing systemic exposure. In this review, we focus on the history and clinical applications of ADCs approved by the U.S. Food and Drug Administration (<jats:styled-content style=\"fixed-case\">FDA<\/jats:styled-content>) for the treatment of cancer and highlight new <jats:styled-content style=\"fixed-case\">ADC<\/jats:styled-content>s in the drug development pipeline. Three <jats:styled-content style=\"fixed-case\">ADC<\/jats:styled-content>s have received <jats:styled-content style=\"fixed-case\">FDA<\/jats:styled-content> approval thus far. Gemtuzumab ozogamicin, although withdrawn from the U.S. market, may still be an effective treatment modality in subsets of patients with acute myeloid leukemia. Brentuximab vedotin and ado\u2010trastuzumab emtansine have shown improved efficacy and safety data compared with standard chemotherapy for the treatment of advanced lymphoma and breast cancer, respectively. With a number of <jats:styled-content style=\"fixed-case\">ADC<\/jats:styled-content>s with promising preliminary data in the clinical trial pipeline, cancer therapy is moving forward from traditional chemotherapy to targeted treatment modalities driven by the specificity of monoclonal antibodies and advancing biotechnology.<\/jats:p>","DOI":"10.1002\/phar.1687","type":"journal-article","created":{"date-parts":[[2016,1,22]],"date-time":"2016-01-22T09:04:18Z","timestamp":1453453458000},"page":"99-116","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Antibody\u2010Drug Conjugates: A Clinical Pharmacy Perspective on an Emerging Cancer Therapy"],"prefix":"10.1002","volume":"36","author":[{"given":"Taleen V.","family":"Jerjian","sequence":"first","affiliation":[{"name":"University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences Aurora Colorado"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashley E.","family":"Glode","sequence":"additional","affiliation":[{"name":"University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences Aurora Colorado"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa A.","family":"Thompson","sequence":"additional","affiliation":[{"name":"University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences Aurora Colorado"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cindy L.","family":"O'Bryant","sequence":"additional","affiliation":[{"name":"University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences Aurora Colorado"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,1,21]]},"reference":[{"doi-asserted-by":"publisher","key":"e_1_2_8_2_1","DOI":"10.1158\/1078-0432.CCR-11-1417"},{"doi-asserted-by":"publisher","key":"e_1_2_8_3_1","DOI":"10.1038\/nrd3980"},{"unstructured":"Seattle Genetics 2015","key":"e_1_2_8_4_1"},{"doi-asserted-by":"publisher","key":"e_1_2_8_5_1","DOI":"10.1038\/nbt832"},{"unstructured":"Adult Hodgkin Lymphoma Treatment (PDQ\u00ae).National Cancer Institute. Available fromhttp:\/\/www.cancer.gov\/cancertopics\/pdq\/treatment\/adulthodgkins\/HealthProfessional. Accessed January 14 2015.","key":"e_1_2_8_6_1"},{"doi-asserted-by":"publisher","key":"e_1_2_8_7_1","DOI":"10.1200\/JCO.2011.38.0410"},{"doi-asserted-by":"publisher","key":"e_1_2_8_8_1","DOI":"10.1016\/S0140-6736(12)60605-9"},{"issue":"9","key":"e_1_2_8_9_1","doi-asserted-by":"crossref","first-page":"3727","DOI":"10.1182\/blood.V90.9.3727","article-title":"Primary anaplastic large\u2010cell lymphoma in adults: clinical presentation, immunophenotype, and outcome","volume":"90","author":"Tilly H","year":"1997","journal-title":"Blood"},{"doi-asserted-by":"publisher","key":"e_1_2_8_10_1","DOI":"10.1200\/JCO.2012.46.0188"},{"doi-asserted-by":"publisher","key":"e_1_2_8_11_1","DOI":"10.1200\/JCO.2011.38.0402"},{"doi-asserted-by":"publisher","key":"e_1_2_8_12_1","DOI":"10.6004\/jnccn.2014.0052"},{"doi-asserted-by":"publisher","key":"e_1_2_8_13_1","DOI":"10.1056\/NEJMoa1002965"},{"unstructured":"Adcetris (brentuximab vedotin): drug safety communication\u2014progressive multifocal leukoencephalopathy and pulmonary toxicity.U.S. Food and Drug Administration. Available fromhttp:\/\/www.fda.gov\/Safety\/MedWatch\/SafetyInformation\/SafetyAlertsforHumanMedicalProducts\/ucm287710.htm?source&#x003D;govdelivery. Accessed January 14 2015.","key":"e_1_2_8_14_1"},{"doi-asserted-by":"publisher","key":"e_1_2_8_15_1","DOI":"10.1016\/S1470-2045(13)70501-1"},{"doi-asserted-by":"publisher","key":"e_1_2_8_16_1","DOI":"10.1016\/S0140-6736(15)60165-9"},{"doi-asserted-by":"publisher","key":"e_1_2_8_17_1","DOI":"10.1182\/blood-2012-03-418673"},{"doi-asserted-by":"publisher","key":"e_1_2_8_18_1","DOI":"10.1016\/j.bbmt.2014.06.037"},{"doi-asserted-by":"publisher","key":"e_1_2_8_19_1","DOI":"10.1007\/s00277-010-1146-3"},{"unstructured":"ClinicalTrials.gov website. Available fromhttps:\/\/clinicaltrials.gov\/. Accessed June 1 2015.","key":"e_1_2_8_20_1"},{"doi-asserted-by":"publisher","key":"e_1_2_8_21_1","DOI":"10.1126\/science.2999974"},{"unstructured":"Breast Cancer Treatment (PDQ\u00ae).National Cancer Institute. Available fromhttp:\/\/www.cancer.gov\/cancertopics\/pdq\/treatment\/breast\/healthprofessional. Accessed January 14 2015.","key":"e_1_2_8_22_1"},{"unstructured":"National Comprehensive Cancer Network.Breast Cancer (Version 2.2015). Available fromhttp:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast.pdf. Accessed April 30 2015.","key":"e_1_2_8_23_1"},{"doi-asserted-by":"publisher","key":"e_1_2_8_24_1","DOI":"10.3816\/CBC.2003.n.017"},{"doi-asserted-by":"publisher","key":"e_1_2_8_25_1","DOI":"10.1186\/bcr1612"},{"doi-asserted-by":"publisher","key":"e_1_2_8_26_1","DOI":"10.1158\/1078-0432.CCR-07-0701"},{"unstructured":"Genentech.Kadcyla\u00ae[package insert].San Francisco CA;2014.","key":"e_1_2_8_27_1"},{"doi-asserted-by":"publisher","key":"e_1_2_8_28_1","DOI":"10.1158\/0008-5472.CAN-08-1776"},{"doi-asserted-by":"publisher","key":"e_1_2_8_29_1","DOI":"10.1007\/s10549-010-1090-x"},{"doi-asserted-by":"publisher","key":"e_1_2_8_30_1","DOI":"10.1056\/NEJMoa1209124"},{"doi-asserted-by":"publisher","key":"e_1_2_8_31_1","DOI":"10.1016\/S1470-2045(14)70178-0"},{"doi-asserted-by":"publisher","key":"e_1_2_8_32_1","DOI":"10.1200\/JCO.2009.26.2071"},{"doi-asserted-by":"publisher","key":"e_1_2_8_33_1","DOI":"10.1007\/s00280-011-1817-3"},{"doi-asserted-by":"publisher","key":"e_1_2_8_34_1","DOI":"10.1186\/bcr3661"},{"key":"e_1_2_8_35_1","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.15_suppl.507","article-title":"Phase III, randomized study of trastuzumab emtansine (T\u2010DM1)\u00a0\u00b1\u00a0pertuzumab (P) vs trastuzumab\u00a0+\u00a0taxane (HT) for first\u2010line treatment of HER2\u2010positive MBC: primary results from the MARIANNE study [abstract 507]","volume":"33","author":"Ellis PA","year":"2015","journal-title":"J Clin Oncol"},{"unstructured":"Hoffmann\u2010La Roche.A study of trastuzumab emtansine (T\u2010DM1) sequentially with anthracycline\u2010based chemotherapy as adjuvant or neoadjuvant therapy for patients with early stage Herceptin (HER)2\u2010positive breast cancer. In: ClinicalTrials.gov [Internet].Bethesda MD:National Library of Medicine (US). Available fromhttps:\/\/clinicaltrials.gov\/ct2\/show\/NCT01196052[cited 2015 May 12]. NLM Identifier: NCT01196052 2000.","key":"e_1_2_8_36_1"},{"unstructured":"Adult Myeloid Leukemia Treatment (PDQ\u00ae).National Cancer Institute. Available fromhttp:\/\/www.cancer.gov\/cancertopics\/pdq\/treatment\/adultAML\/healthprofessional. Accessed January 14 2015.","key":"e_1_2_8_37_1"},{"unstructured":"Wyeth.Mylotarg\u00ae[package insert].Philadelphia PA;2005.","key":"e_1_2_8_38_1"},{"doi-asserted-by":"publisher","key":"e_1_2_8_39_1","DOI":"10.1200\/JCO.2001.19.13.3244"},{"doi-asserted-by":"publisher","key":"e_1_2_8_40_1","DOI":"10.1182\/blood-2013-01-466706"},{"doi-asserted-by":"publisher","key":"e_1_2_8_41_1","DOI":"10.1182\/blood-2013-03-490482"},{"doi-asserted-by":"crossref","unstructured":"DelaunayJ RecherC PigneuxA et\u00a0al.Addition of gemtuzumab ozogamycin to chemotherapy improves event\u2010free survival but not overall survival of AML patients with intermediate cytogenetics not eligible for allogenic transplantation. Results of the GOELAMS AML 2006 IR study [Abstract #79]. Presented at the 53rd American Society of Hematology Annual Meeting and Exposition.San Diego CA December 11 2011.","key":"e_1_2_8_42_1","DOI":"10.1182\/blood.V118.21.79.79"},{"doi-asserted-by":"publisher","key":"e_1_2_8_43_1","DOI":"10.1111\/bjh.12528"},{"doi-asserted-by":"publisher","key":"e_1_2_8_44_1","DOI":"10.1007\/s00277-014-2218-6"},{"unstructured":"About FDA: Gemtuzumab Ozogamicin.U.S. Food and Drug Administration. Available fromhttp:\/\/www.fda.gov\/AboutFDA\/CentersOffices\/OfficeofMedicalProductsandTobacco\/CDER\/ucm216790.htm. Accessed January 30 2015.","key":"e_1_2_8_45_1"},{"doi-asserted-by":"publisher","key":"e_1_2_8_46_1","DOI":"10.1093\/annonc\/mdt566"},{"doi-asserted-by":"publisher","key":"e_1_2_8_47_1","DOI":"10.1016\/S1470-2045(14)70281-5"},{"doi-asserted-by":"publisher","key":"e_1_2_8_48_1","DOI":"10.1200\/JCO.2010.31.4310"},{"doi-asserted-by":"publisher","key":"e_1_2_8_49_1","DOI":"10.1016\/j.leukres.2014.11.027"},{"doi-asserted-by":"publisher","key":"e_1_2_8_50_1","DOI":"10.1038\/leu.2012.229"},{"doi-asserted-by":"publisher","key":"e_1_2_8_51_1","DOI":"10.1182\/blood-2013-06-506592"},{"doi-asserted-by":"publisher","key":"e_1_2_8_52_1","DOI":"10.1200\/JCO.2013.49.0771"},{"doi-asserted-by":"publisher","key":"e_1_2_8_53_1","DOI":"10.3109\/10428194.2014.986478"},{"doi-asserted-by":"publisher","key":"e_1_2_8_54_1","DOI":"10.1002\/cncr.28334"},{"doi-asserted-by":"publisher","key":"e_1_2_8_55_1","DOI":"10.1200\/JCO.2014.55.3628"},{"doi-asserted-by":"publisher","key":"e_1_2_8_56_1","DOI":"10.1517\/14712598.2011.543895"},{"issue":"5","key":"e_1_2_8_57_1","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1182\/blood.V71.5.1480.1480","article-title":"Expression and structure of CD22 in acute leukemia","volume":"71","author":"Bou\u00e9 DR","year":"1988","journal-title":"Blood"},{"doi-asserted-by":"publisher","key":"e_1_2_8_58_1","DOI":"10.1200\/EdBook_AM.2013.33.294"},{"doi-asserted-by":"publisher","key":"e_1_2_8_59_1","DOI":"10.1002\/cncr.28136"},{"unstructured":"Pfizer phase 3 study of inotuzumab ozogamicin meets primary endpoint in adult patients with relapsed or refractory acute lymphoblastic leukemia. Pfizer Web site. Available fromhttp:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer_phase_3_study_of_inotuzumab_ozogamicin_meets_primary_endpoint_in_adult_patients_with_relapsed_or_refractory_acute_lymphoblastic_leukemia. Accessed September 22 2015.","key":"e_1_2_8_60_1"},{"doi-asserted-by":"publisher","key":"e_1_2_8_61_1","DOI":"10.1200\/JCO.2012.42.7211"},{"issue":"6","key":"e_1_2_8_62_1","first-page":"1927","article-title":"Rituximab (anti\u2010CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study","volume":"92","author":"Coiffier B","year":"1998","journal-title":"Blood"},{"doi-asserted-by":"publisher","key":"e_1_2_8_63_1","DOI":"10.3109\/10428194.2015.1017821"},{"doi-asserted-by":"publisher","key":"e_1_2_8_64_1","DOI":"10.1200\/JCO.2009.25.1900"},{"doi-asserted-by":"publisher","key":"e_1_2_8_65_1","DOI":"10.1182\/blood.V70.5.1316.1316"},{"doi-asserted-by":"publisher","key":"e_1_2_8_66_1","DOI":"10.1158\/1078-0432.CCR-13-0580"},{"doi-asserted-by":"crossref","unstructured":"CoiffierB ThieblemontC deGuibertS et\u00a0al.Phase II study of antiCD19 antibody drug conjugate (SAR3419) in combination with rituximab: clinical activity and safety in patients with relapsed\/refractory diffuse large B\u2010Cell lymphoma [abstract 4395]. Presented at the 55th American Society of Hematology Annual Meeting and Exposition.New Orleans LA December 9 2013.","key":"e_1_2_8_67_1","DOI":"10.1182\/blood.V122.21.4395.4395"},{"doi-asserted-by":"publisher","key":"e_1_2_8_68_1","DOI":"10.1038\/leu.2015.48"},{"issue":"5","key":"e_1_2_8_69_1","article-title":"Preliminary results of a phase II randomized study (ROMULUS) of polatuzumab vedotin (PoV) or pinatuzumab vedotin (PiV) plus rituximab (RTX) in patients (Pts) with relapsed\/refractory (R\/R) non\u2010Hodgkin lymphoma (NHL) [abstract 8519]","volume":"32","author":"Morschhauser F","year":"2014","journal-title":"J Clin Oncol"},{"doi-asserted-by":"publisher","key":"e_1_2_8_70_1","DOI":"10.1158\/1078-0432.CCR-05-2018"},{"doi-asserted-by":"publisher","key":"e_1_2_8_71_1","DOI":"10.1158\/1078-0432.CCR-09-1611"},{"key":"e_1_2_8_72_1","first-page":"839","article-title":"Glycoprotein non\u2010metastatic b (GPNMB): a metastatic mediator and emerging therapeutic target in cancer","volume":"6","author":"Maric G","year":"2013","journal-title":"Onco Targets Ther"},{"issue":"15","key":"e_1_2_8_73_1","article-title":"Frequent dosing and GPNMB expression with CDX011 (CR011vcMMAE), an antibody\u2010drug conjugate (ADC), in patients with advanced melanoma [abstract 8525]","volume":"28","author":"Hamid O","year":"2010","journal-title":"J Clin Oncol"},{"issue":"24","key":"e_1_2_8_74_1","article-title":"A phase (Ph) I\/II study of CR011VcMMAE, an antibody\u2010drug conjugate, in patients (pts) with locally advanced or metastatic breast cancer (MBC) [abstract 6096]","volume":"69","author":"Burris H","year":"2009","journal-title":"Cancer Res"},{"issue":"24","key":"e_1_2_8_75_1","article-title":"A randomized phase 2 study of the antibody\u2010drug conjugate CDX011 in advanced GPNMB\u2010overexpressing breast cancer: the EMERGE study [abstract P6\u201010\u201001]","volume":"72","author":"Yardley DA","year":"2012","journal-title":"Cancer Res"},{"issue":"1","key":"e_1_2_8_76_1","first-page":"81","article-title":"Prostate\u2010specific membrane antigen expression in normal and malignant human tissues","volume":"3","author":"Silver DA","year":"1997","journal-title":"Clin Cancer Res"},{"issue":"17","key":"e_1_2_8_77_1","first-page":"6357","article-title":"Correlation of primary tumor prostate\u2010specific membrane antigen expression with disease recurrence in prostate cancer","volume":"9","author":"Ross JS","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"7","key":"e_1_2_8_78_1","article-title":"A phase 2 study of prostate specific membrane antigen antibody drug conjugate (PSMA ADC) in patients (pts) with progressive metastatic castration\u2010resistant prostate cancer (mCRPC) following abiraterone and\/or enzalutamide (abi\/enz) [abstract 144]","volume":"33","author":"Petrylak DP","year":"2015","journal-title":"J Clin Oncol"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fphar.1687","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fphar.1687","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.1687","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:27:09Z","timestamp":1761042429000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/phar.1687"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":77,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["10.1002\/phar.1687"],"URL":"https:\/\/doi.org\/10.1002\/phar.1687","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"type":"print","value":"0277-0008"},{"type":"electronic","value":"1875-9114"}],"subject":[],"published":{"date-parts":[[2016,1]]},"assertion":[{"value":"2016-01-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}